Bausch Advances Novel Dry Eye Therapeutic to Phase 3
Tuesday, December 29 2020 | 07 h 28 min | News
Quebec based B+L has announced the second of two Phase 3 studies studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in- class investigational drug to treat the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian gland dysfunction (MGD).
According to the company, the new proprietary compound NOV03 is a proprietary, water-free and preservative-free solution, based on patented EyeSol® technology from German company, Novaliq GmbH. The drug has a novel mechanism of action to treat Dry Eye Disease associated with MGD.
NOV03 showed statistically significant improvement of certain symptoms, such as severity and frequency of dryness and burning/stinging of the eyes, over the entire duration of the Phase 2 study (336 patients) with no notable safety events.
